The combination of HER2-targeted agents is already approved for use in breast cancer and is now is the first treatment approved for HER2-positive colorectal cancer.
FDA Approvals
Tucatinib Plus Trastuzumab Approved for HER2+ CRC
The combination of HER2-targeted agents is already approved for use in breast cancer and is now is the first treatment approved for HER2-positive colorectal cancer.
FDA Approvals
